10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2013

Commission file number 0-13092

SPECTRASCIENCE, INC.

 (Exact name of registrant

as specified in its charter)

Minnesota	41-1448837
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

11568 Sorrento Valley Rd., Suite 11

San Diego, California 92121

(Address of principal executive offices, including zip code)

(858) 847-0200

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   YES x     NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registration was required to submit and post such files). YES  x    NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer        o	Accelerated filer                  o
Non-accelerated filer           o	Smaller reporting company        x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ¨ NO x

The number of shares of the registrant’s common stock, par value $0.01 per share, outstanding on May 20, 2013 was 159,253,139.

SPECTRASCIENCE, INC.

FORM 10-Q

For the Quarterly Period Ended March 31, 2013

TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION:
Item 1.	Financial Statements (Unaudited)	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	17
Item 4.	Controls and Procedures	17
PART II	OTHER INFORMATION
Item 1.	Legal Proceedings	18
Item 1A.	Risk Factors	18
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
Item 3.	Defaults Upon Senior Securities	18
Item 4.	Mine Safety Disclosures	18
Item 5.	Other Information	18
Item 6.	Exhibits	18
SIGNATURES		19

2

PART I     FINANCIAL INFORMATION:

Item 1. Financial Statements (Unaudited)

SpectraScience, Inc. and Subsidiaries

CONSOLIDATED BALANCE SHEETS

	March 31, 2013			December 31, 2012
	(Unaudited)
ASSETS
Current assets:
Cash	$	237,162		$	90,192
Inventories		205,475			202,077
Deferred debt issuance costs		284,050			165,649
Prepaid expenses and other current assets		175,212			191,030
Total current assets		901,899			648,948
Fixed assets, net		67,151			85,592
Patents, net		1,637,425			1,678,787
TOTAL ASSETS	$	2,606,475		$	2,413,327
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	897,279		$	861,698
Convertible debt		1,857,894			1,129,473
Discount		(886,241	)		(520,851	)
Convertible debt, net		971,653			608,622
Derivative liability		4,388,830			2,335,560
Accrued expenses		214,677			183,855
Total current liabilities		6,472,439			3,989,735
COMMITMENTS
SHAREHOLDERS’ EQUITY (DEFICIT)
Series B Convertible Preferred Stock, $.01 par value:
Authorized – 2,585,000 shares; shares issued and outstanding - 2,585,000 shares at March 31, 2013 and December 31, 2012, liquidation value of $517,000 plus accumulated and unpaid dividends of $106,931 as of March 31, 2013 and December 31, 2012		25,850			25,850
Series C Convertible Preferred Stock, $.01 par value:
Authorized – 1,000,000 shares; shares issued and outstanding -1,000,000 shares at March 31, 2013 and December 31, 2012, $200,000 liquidation value		10,000			10,000
Common stock, $.01 par value:
Authorized — 275,000,000 shares; Issued and outstanding -157,654,565 shares at March 31, 2013 and 152,229,665 shares at December 31, 2012		1,576,546			1,522,297
Additional paid-in capital		35,770,894			35,491,603
Accumulated deficit		(41,249,254	)		(38,626,158	)
TOTAL SHAREHOLDERS’ (DEFICIT)		(3,865,964	)		(1,576,408	)
TOTAL LIABILITIES AND SHAREHOLDERS’ (DEFICIT)	$	2,606,475		$	2,413,327

Note: The balance sheet at December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information required by accounting principles generally accepted in the United States of America for complete financial statements.

See accompanying notes to unaudited financial statements.

3

SpectraScience, Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended  March 31,
	2013			2012
Revenue	$	-		$	-
Cost of revenue		-			-
Gross profit		-			-
Operating expenses:
Research and development		187,457			380,286
General and administrative		497,703			547,645
Sales and marketing		77,374			108,696
Total operating expenses		762,545			1,036,627
Loss from operations		(762,545	)		(1,036,627	)
Other expense (income)
Interest expense		56,581			38,028
Change in fair value of derivative liabilities		1,116,019			1,582,406
Amortization of debt liability discount		464,068			351,425
Amortization of deferred debt issuance costs and original issue discount		190,569			143,571
Loss on extinguishment of debt		30,796			-
Other expense (income), net		2,518			(56	)
		1,860,551			2,115,374
Net (Loss)	$	(2,623,096	)	$	(3,152,001	)
Basic and diluted net (loss) per share	$	(0.02	)	$	(0.03	)
Weighted average common shares outstanding - basic and diluted		155,871,102			108,041,084

See accompanying notes to unaudited financial statements.

4

SpectraScience, Inc. and Subsidiary

CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY (DEFICIT)

For the three months ended March 31, 2013

(Unaudited)

	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance, December 31, 2012		3,585,000	$	35,850		152,229,665	$	1,522,297	$	35,491,603	$	(38,626,158	)	$	(1,576,408	)
Stock based compensation – consultants										2,106					2,106
Stock based compensation – employees										99,642					99,642
Common stock issued for services						3,000,000		30,000		25,149					55,149
Conversion of convertible debt						2,424,900		24,249		152,394					176,643
Net loss												(2,623,096	)		(2,623,096	)
Balance, March 31, 2013		3,585,000	$	35,850		157,654,565	$	1,576,546	$	35,770,894	$	(41,249,254	)	$	(3,865,964	)

See accompanying notes to unaudited financial statements.  

5

SpectraScience, Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended  March 31,
	2013			2012
OPERATING ACTIVITIES:
Net loss	$	(2,623,096	)	$	(3,152,001	)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization		59,803			88,906
Amortization of derivative and warrant liabilities discount		464,068			351,425
Amortization of deferred debt issuance costs and original issue discount		190,569			143,571
Change in fair value of derivative and warrant liabilities		1,116,019			1,582,406
Loss on extinguishment of debt		30,796			-
Stock-based compensation employees		99,642			92,457
Stock-based compensation consultants		2,106			7,121
Fair market value of common stock issued for services		55,149			-
Changes in operating assets and liabilities:
Accounts receivable		-			-
Inventories		(3,398	)		(76,932	)
Prepaid expenses and current other assets		15,818			(2,050	)
Accounts payable		35,581			(99,833	)
Accrued expenses		50,413			(30,288	)
Net cash (used in) operating activities		(506,590	)		(1,095,218	)
INVESTING ACTIVITIES:
Purchases of fixed assets		-			(4,170	)
Net cash from (used in) investing activities		-			(4,170	)
FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes payable		812,000			2,233,000
Debt issuance costs		(158,440	)		(379,402	)
Net cash provided by financing activities		653,560			1,853,598
Net increase in cash		146,970			754,210
CASH AT BEGINNING OF PERIOD		90,192			250,723
CASH AT END OF PERIOD	$	237,162		$	1,004,933
Non Cash investing and financing activities
Convertible debt and accrued interest converted to common stock	$	138,948			-
Convertible debt and warrant liability discounts recorded at issuance	$	812,000		$	2,212,928
Deferred debt issuance costs recorded at issuance	$	125,251		$	435,788

See accompanying notes to unaudited financial statements.

6

SpectraScience, Inc. and Subsidiaries

Notes to Unaudited Condensed Financial Statements

March 31, 2013

1.     Nature of Business and Basis of Presentation

Description of Business

SpectraScience, Inc. was incorporated in the State of Minnesota on May 4, 1983 as GV Medical, Inc. In October 1992, GV Medical discontinued its prior business, refocused its development efforts and changed its name to SpectraScience, Inc. The “Company,” hereinafter, refers to SpectraScience, Inc. and its wholly owned subsidiaries Luma Imaging Corporation (“LUMA”) and Spectra Science International, Inc. (“International”). From 1996, the Company primarily focused on developing the WavSTAT Optical Biopsy System (the “WavSTAT System”). 

The Company has developed and received the European CE mark approval to market a proprietary, minimally invasive technology that optically illuminates tissue in real-time to distinguish between normal, pre-cancerous or cancerous cells without the need to remove the subject cell tissue from the body to make such determinations. The WavSTAT System operates by using cool, safe laser light to optically illuminate and analyze tissue, enabling the physician to make an instant diagnosis during endoscopy when screening for cancer, and if warranted, to begin immediate treatment during the same procedure. Beginning in December 2011, the WavSTAT 4 version of the product began to be sold in the European Union for colon cancer detection. In June 2012, the Company entered into a distribution agreement with PENTAX Europe, GmbH, for the sale of its systems internationally.

On November 6, 2007, the Company acquired the assets of LUMA in an equity transaction accounted for as an acquisition of assets and now operates LUMA as a wholly-owned subsidiary of the Company. LUMA had acquired the assets from a predecessor company that had developed, and received FDA approval for, a non-invasive diagnostic imaging system that can detect cervical cancer precursors and which utilizes an underlying technology that is similar to that of the WavSTAT System. The addition of the LUMA technology to the Company’s existing WavSTAT System technology provides the Company with a broad suite of fluorescence-based intellectual property and know-how. During the fiscal year ended December 31, 2010, the Company wrote off the remaining fair value of the LUMA inventory in order to focus on the continued development and marketing of the WavSTAT System. The Company retained the intellectual property of LUMA for use in the development of future generations of the WavSTAT System.

The transaction was accounted for as an acquisition of assets that included intellectual property, inventory and equipment. The intellectual property consisted of a total of 34 issued U.S. patents and 28 additional patent applications.

Basis of Presentation

The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are prescribed for smaller reporting companies. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the three-month period ended March 31, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. These statements should be read in conjunction with the financial statements and related notes, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

Liquidity and Capital Resources

Historically, the Company’s sources of cash have come from the issuance and sales of equity securities, convertible debentures and interest income. The Company’s historical cash outflows have been primarily used for operating activities including research, development, administrative and sales activities. Fluctuations in the Company’s working capital due to timing differences of its cash receipts and cash disbursements also impact its cash flow. The Company expects to incur significant additional operating losses through at least the end of 2013, as it completes proof-of-concept trials, conducts outcome-based clinical studies and increases sales and marketing efforts to commercialize the WavSTAT4 Systems in Europe. If the Company does not receive sufficient funding, the Company may be unable to continue as a going concern. The Company may incur unknown expenses or may not be able to meet its revenue forecast, and one or more of these circumstances would require the Company to seek additional capital. The Company may not be able to obtain equity capital or debt funding on terms that are acceptable. Even if the Company receives additional funding, such proceeds may not be sufficient to allow the Company to sustain operations until it becomes profitable and begins to generate positive cash flows from operations.

7

As of March 31, 2013, the Company had a working capital deficit of approximately $5.6 million and cash of approximately $237,000, compared to working capital deficit of approximately $3.3 million and cash of approximately $90,000 as of December 31, 2012. In December 2011, the Company entered into an Engagement Agreement with Laidlaw & Company (UK) Ltd., which Engagement Agreement was amended in July 2012. Under the Engagement Agreement, Laidlaw agreed to assist the Company in raising up to $20.0 million in capital over a two year period from the date of the Engagement Agreement. During the fiscal quarter ended March 31, 2013, the Company raised approximately $654,000, net of transaction costs, under this agreement. However, if the Company does not receive additional funds in a timely manner, the Company could be in jeopardy as a going concern. The Company may not be able to find alternative capital or raise capital or debt on terms that are acceptable. Management believes that if the events defined in the Engagement Agreement occur as expected, such proceeds will be sufficient to allow the Company to sustain operations until it attains profitability and positive cash flows from operations. However, the Company may incur unknown expenses or may not be able to meet its revenue expectations requiring it to seek additional capital. In such event, the Company may not be able to find capital or raise capital or debt on terms that are acceptable.

The Company paid principal and interest owing on Convertible Debentures that have been converted by issuing shares of common stock. The holders of Convertible Debentures control the conversion of the Convertible Debentures and certain of the Convertible Debentures were not converted at their maturity constituting a potential default on these remaining matured, but unconverted, Convertible Debentures. The holders of these unconverted Convertible Debentures have the option to declare their Convertible Debentures in default. In the event of such default, principal, accrued interest and other related costs are immediately due and payable in cash.

During the three months ended March 31, 2013, Convertible Debentures with a face value of approximately $479,000 held by thirteen individual investors matured. These remain outstanding, but none of these thirteen investors have served notice of default on the Convertible Debentures held by them.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

2.     Summary of Significant Accounting Policies

Revenue recognition

The Company recognizes revenues when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue from the sale of the Company’s products is generally recognized when title and risk of loss transfers to the customer, the terms of which are generally free on board shipping point. The Company uses customer purchase orders to determine the existence of an arrangement. The Company uses shipping documents and third-party proof of delivery to verify that title has transferred. The Company assesses whether the price is fixed or determinable based upon the terms of the agreement associated with the transaction. To determine whether collection is probable, the Company assesses a number of factors, including past transaction history with the customer and the creditworthiness of the customer.

Consolidation

The accompanying consolidated financial statements include the accounts of SpectraScience, Inc. and its wholly-owned subsidiaries LUMA, and International. All significant intercompany balances and transactions have been eliminated in consolidation.

Risks and Uncertainties

The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. The Company's operations are subject to significant risk and uncertainties, including financial, operational, technological, regulatory and other risks associated with a short history of product sales, including the potential risk of business failure.

8

Use of Estimates

The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Significant estimates made by management include, among others, realization of long-lived assets including intangible assets, assumptions used to value stock options, assumptions used to value the common stock issued and assumptions related to the determination of the fair value of the derivative components associated with the Company’s Convertible Debentures. Actual results could differ from those estimates.

Inventory Valuation

The Company records its inventories at the lower of cost or market value, determined on a specific cost basis. The Company provides inventory allowances when conditions indicate that the selling price could be less than cost due to obsolescence and reductions in estimated future demand. The Company balances the need to maintain strategic inventory levels with the risk of obsolescence due to changing technology and customer demand levels. Unfavorable changes in market conditions may result in a need for additional inventory reserves that could adversely impact the Company’s gross margins. Conversely, favorable changes in demand could result in higher gross margins when the Company sells products.

Valuation of Long-lived Assets

The Company’s long-lived assets consist of fixed assets and intangible assets. Equipment is carried at cost and is depreciated over the estimated useful lives of the assets, which are generally two to three years, and leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the improvements. The straight-line method is used for depreciation and amortization. Intangible assets consist of patents, which are amortized using the straight-line method over the estimated useful lives of the patents. The Company does not capitalize external legal costs and filing fees associated with obtaining patents on its new discoveries. Acquired intellectual property is recorded at fair value and is amortized over its estimated useful life. The Company believes the useful lives assigned to these assets are reasonable. The Company assesses the recoverability of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. These computations utilize judgments and assumptions inherent in management’s estimate of future cash flows to determine recoverability of these assets. If management’s assumptions about these assets were to change as a result of events or circumstances, the Company may be required to record an impairment loss.  

Convertible Debentures/Warrants

We account for our Convertible Debentures, associated warrants and related conversion features under the provisions of FASB Topic 470, Debt, or ASC 470, which requires the measurement and recognition of the fair values for all components related to the Convertible Debentures at the end of each reporting period. We estimate the fair value of the resulting Beneficial Conversion Feature ("BCF"), holders warrants and agent warrants at each measurement date using a combination of the Black-Scholes-Merton and modified Binomial Lattice option-pricing models. These standards require us to record the fair value of the Convertible Debentures, BCF and warrants at the time of issuance and to remeasure these values and record associated income statement expense or benefit at the end of each reporting period.

Stock-Based Compensation

The Company accounts for stock-based compensation under the provisions of FASB ASC Topic 718, Compensation—Stock Compensation   (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company adopted ASC 718 on January 1, 2006. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes-Merton option-pricing model (the “Black-Scholes Model”). The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. The Company estimates forfeitures at the time of grant and revises its estimate in subsequent periods if actual forfeitures differ from those estimates.

The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC Topic 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.

All issuances of stock options or other equity instruments to employees and non-employees as the consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Any stock options issued to non-employees are recorded in expense and additional paid-in capital in shareholders’ equity over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options at the end of each reporting period.

As of March 31, 2013, the Company had one stock-based employee compensation plan under which it makes grants, the 2011 Equity Incentive Plan (the “EIP”). The EIP provides for the grant of incentive stock options (“ISOs”), nonqualified stock options (“NQSOs”) and restricted stock awards to full-time employees (who may also be directors) and NQSOs and restricted stock awards to non-employee directors, consultants, customers, vendors or providers of services. The exercise price of any ISO may not be less than the fair market value of the common stock on the date of grant and the term shall not exceed ten years. The amount reserved under the 2011 EIP is 15,000,000 shares of common stock.  At March 31, 2013, the Company had outstanding 19,491,667 options under the EIP and the Company’s prior Amended 2001 Stock Plan representing approximately 13% of the Company’s outstanding shares (10,141,979 of which were exercisable), with 6,453,333 available for future issuance under the 2011 EIP. Awards under the Company’s EIP generally vest over four years.

The fair value of options granted were estimated at the date of grant using a Black-Scholes Model which includes several variables including expected life, risk free interest rate, expected stock price volatility, stock option exercise patterns and expected dividend yield. The Company also must estimate forfeitures for employee stock options. These models and assumptions are complex and may change future expenses by increasing or decreasing stock-based compensation expense. There were no stock options granted during the three month period ended March 31, 2013. Management used the following weighted average assumptions to value stock options granted during the three months ended March 31, 2013 and 2012:

9

	2013		2012
Expected life	-		5 Years
Risk-free interest rate		-		.85	%
Expected volatility		-		113	%
Expected dividend yield		-		0	%

Management believes estimated forfeitures for employee stock options granted under the EIP would have a negligible effect on expenses because such forfeitures would be a very small percentage. Stock option grants have been to a group of individuals that have a high desire to see the Company succeed and have aligned themselves to that end.  

The expected lives used in the calculations were selected by management based on past experience, forward looking profit forecasts and estimates of what the trading price of the Company’s stock might be at different future dates.

The risk-free interest rates used in the calculations are the five-year U.S. Treasury rates as published on the date of the applicable stock option grant.

Volatility is a calculation based on fluctuations in the Company’s stock price over a historical time period consistent with the estimated life of the option.

Options outstanding that have vested and those that remain unvested as of March 31, 2013 are as follows:

			Weighted		Weighted Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual Term in		Intrinsic
	Shares		Price		Years		Value(1)
Vested		10,414,979	$	0.23		6.56	$	-
Unvested		9,349,688		0.13		8.69		-
Total		19,491,667	$	0.18		7.58	$	-

(1) These amounts represent the excess, if any, between the exercise price and $0.05, the closing market price of the Company’s common stock on March 31, 2013 as quoted on the Over-the-Counter Bulletin Board under the symbol “SCIE”.

Additional information with respect to stock option activity is as follows: 

			Outstanding Options
	Options Available For Grant		Plan Options Outstanding		Weighted Average Exercise Price Per Share		Weighted-Average Remaining Contractual  Term (years)		Aggregate Intrinsic Value
December 31, 2012		6,453,333		19,491,667	$	0.18		8.20		-
Options granted		-		-		-		-		-
Options exercised		-		-		-		-		-
Options forfeited		-		-		-		-		-
Additional options authorized		-		-		-		-		-
Outstanding at March 31, 2013		6,453,333		19,491,667	$	0.18		7.58		-
Exercisable at March 31, 2013		-		10,141,979	$	0.23		6.56		-

There were no options exercised during the three months ended March 31, 2013 and 2012. At March 31, 2013, total unrecognized estimated employee compensation cost related to non-vested stock options granted prior to that date is approximately $739,000, which is expected to be recognized over the next four years.

10

Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share is computed similarly to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and only if the additional common shares would be dilutive. Potentially dilutive shares of common stock that have been excluded from the calculation of the weighted average number of dilutive common shares for the three-months ended March 31, 2013 include common stock purchase warrants to acquire 70,210,121 shares of common stock, stock options to purchase 19,491,667 shares of common stock and preferred stock convertible into 3,585,000 shares of common stock.

The following table sets forth the computation of basic and diluted earnings per share and incorporates any additional income related to the change in fair value of derivative securities for the three-month period ending March 31, 2013:

	For the Three			For the Three
	Months Ended			Months Ended
	March 31,			March 31,
	2013			2012
Numerator:
Net (loss) for basic earning per share		(2,623,096	)		(3,152,001	)
Subtractions:
Change in fair value of derivative securities		-			-
Net (loss) for diluted earnings per share		(2,623,096	)		(3,152,001	)
Denominator:
Weighted average basic shares outstanding		155,871,102			108,041,084
Assumed conversion of dilutive securities
Warrants		-			-
Conversion feature - Convertible Debentures		-			-
Potentially dilutive common shares		-			-
Denominator for diluted earnings per share - Adjusted weighted average shares		155,871,102			108,041,084
(Loss) per share
Basic	$	(0.02	)	$	(0.03	)
Diluted	$	(0.02	)	$	(0.03	)

Inventories

Inventories consisted of the following at March 31, 2013 and December 31, 2012:

	March 31, 2013		December 31, 2012
Raw materials	$	158,420	$	155,022
Finished goods		47,055		47,055
Totals	$	205,475	$	202,077

11

3. Liabilities

Convertible Debentures

For the three-month period ended March 31, 2013, the Company issued Convertible Debentures (“Debentures”) at a face amount of $854,737. At March 31, 2013, the unamortized discount of $886,241 consisted of a discount on the derivative liability of $495,203, discount on the warrant liability of $345,596 and original issue discount of $45,442. The discounts will be amortized over the remaining term of the Debentures. The Debentures have an original term of six months, accrue interest at rates ranging from 16-20% per year, carry an original issue discount of 5% and will convert into common stock at an initial conversion price ranging from $0.0573 to $0.099 per share at maturity. The Debentures were issued with detachable five-year cashless warrants (“Holders Warrants”) that allow the holders to purchase one share of stock for each two shares available under the converted Debentures at an exercise price ranging from $0.0745 to $0.1287 per share. In addition, the Company issued five-year cashless Agent Warrants equal to 10% of the total number of shares issuable under the Debentures and Holders Warrants at an exercise price ranging from $0.0745 to $0.1287 per share. At March 31, 2013, there were Debentures, Holders Warrants and Agent Warrants convertible or exercisable into 27,796,733, 34,409,070 and 9,824,338 shares of common stock, respectively. The conversion price of the Debentures and Holders Warrants are subject to an adjustment feature in the event that the Company issues securities for less than the conversion price of the Debentures. The Holders and Agent Warrants contain a provision under which the Warrants, under certain circumstances, could be acquired for a presently undetermined consideration at a future date. The accounting for the adjustment features of the conversion price for the debt and the warrant exercise price for the Holders’ Warrants is described separately below under, “Warrant Liability” and “Derivative Liability”. For the three-month period ended March 31, 2013, upon issuance of the Debentures the Company received net cash proceeds of $653,560, net of $158,440 in transaction costs and $42,737 of original issue discount. For the three-month period ended March 31, 2013, Debentures with a face value of $126,316 and accrued interest of $12,632 were converted at a price of $0.0573 into 2,424,900 shares of common stock. At March 31, 2013, Debentures with a face value of approximately $479,000 were in default and accruing interest at a default rate of 20% per year.

Warrant Liability

The Company issued Convertible Debentures, which included Holders Warrants (“Securities”). In addition, the Company issued Agent warrants to Laidlaw & Co. Ltd. as compensation related to the sale of the Securities. The Holders Warrants include a possible adjustment feature in the event of a future financing on terms more favorable than those of the existing Securities. Additionally, the Holders and Agent Warrants also contain a provision that provides for specific consideration in the event of certain all cash or private change of control transactions. This results in the Holders and Agent Warrants being classified as “Derivative Warrants”. The accounting guidance requires that these warrants be recorded as a liability and measured at fair value on a recurring basis. The Company records the fair value of these warrants in its statement of operations in the line “Change in fair value of derivative liabilities.” The Company measures these warrants using a combination of Black-Scholes option valuation models and Binomial Lattice option valuation models using similar assumptions to those described under “Stock-Based Compensation.” At March 31, 2013, there were exercisable warrants to purchase 44,233,408 shares of common stock. The time period over which the Company will be required to evaluate the fair value of these warrants is approximately five years. For the three-month period ended March 31, 2013, upon issuance of the Debentures, the Company recorded an additional Warrant Liability of $762,111 of which $306,640 was recognized as an immediate non-cash expense and the remaining amount is being amortized over the life of the associated Debentures (generally, six-months).

The Company computes the fair value of the warrant liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the warrant liability is the Company’s stock price, which is subject to significant fluctuation and is not under the Company’s control. The resulting effect on the Company’s net loss is therefore subject to significant fluctuation and will continue to be so until the Derivative Warrants expire (approximately five years from the date of issuance). Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.

The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment of the probability of a more favorably priced future financing or significant fluctuations in the volatility of the trading market for the Company’s common stock the Company’s fair value estimates could be materially different in the future.

12

Derivative Liability

During the three-month period ended March 31, 2013, the Company issued convertible Debentures with a conversion price that includes a possible exercise adjustment feature in the event that it issues securities for consideration less than that offered with the convertible Debentures (referred to as “Derivative Liabilities”). The Company records the fair value of the conversion feature in its statement of operations in the line “Change in fair value of derivative liabilities.” The Company measures the conversion feature using a Binomial Lattice option valuation model using similar assumptions to those described under “Stock-Based Compensation.” At March 31, 2013, there were convertible shares to purchase 27,796,733 shares of common stock subject to this price adjustment feature. The time period over which the Company will be required to evaluate the fair value of this conversion feature is the lesser of six months or conversion. For the three-month period ended March 31, 2013, upon issuance of the Debentures, the Company recorded a derivative liability of $929,156 and an initial fair value non-cash expense of $447,376. Convertible Debentures with a face value of $126,316 converted into approximately 2,425,000 shares of Common Stock.

The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Debentures, which the convertible feature is associated with, mature. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.

The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, the Company’s fair value estimates could be materially different in the future.

4. Shareholders’ Equity

Common Stock

In January 2013, the Company issued 3,000,000 shares of restricted common stock to two vendors for services. The fair value of the vested portion of these shares was determined to be $55,149.

In February of 2013, holders of Convertible Debentures with a face value of $126,316 converted their debentures into 2,204,453 shares of restricted common stock. In addition, associated with these debentures, the Company paid $12,632 in accrued interest by issuing 220,447 shares of restricted common stock.

Warrants

During the three-months ended March 31, 2013, in conjunction with the sale of Convertible Debentures, the Company issued five-year common stock purchase warrants to acquire 7,458,437 shares to holders of the Debentures and 2,237,531 similar warrants as compensation to Agents. These warrants have an exercise price of $0.0745 per share.

Convertible Debentures

During the three-months ended March 31, 2013, the Company entered into subscription agreements with accredited investors to purchase an aggregate principal amount of $854,737 of Convertible Debentures initially convertible into shares of restricted common stock at a conversion price of $0.0573.

5. Fair Value Measurements

Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.

The Company's balance sheet contains derivative and warrant liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:

Level 1: uses quoted market prices in active markets for identical assets or liabilities.

Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: uses unobservable inputs that are not corroborated by market data.

The fair value of the Company’s recorded derivative and warrant liabilities is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. Binomial Lattice and Black Scholes option valuation models were used to determine the fair value with similar assumptions to those described under “Stock-Based Compensation”. The Company records derivative and warrant liabilities on the consolidated balance sheets at fair value with changes in fair value recorded in the consolidated statements of operations.

The following table presents the balances of liabilities measured at fair value on a recurring basis by level as of December 31, 2012 and March 31, 2013:

13

	Fair Value Measurements Using
	Quoted Prices in		Significant Other		Significant
	Active Markets for		Observable		Unobservable
	Identical Assets		Inputs		Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
As of December 31, 2012
Derivative liability	$	-	$	-	$	605,516	$	605,516
Warrant liability		-		-		1,730,044		1,730,044
Total	$	-	$	-	$	2,335,560	$	2,335,560

	Fair Value Measurements Using
	Quoted Prices in		Significant Other		Significant
	Active Markets for		Observable		Unobservable
	Identical Assets		Inputs		Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
As of March 31, 2013
Derivative liability	$	-	$	-	$	1,752,974	$	1,752,974
Warrant liability		-		-		2,635,856		2,635,856
Total	$	-	$	-	$	4,388,830	$	4,388,830

The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the three months ended March 31, 2013:

	Warrant			Derivative			Total
	Liability			Liability			Liability
Balance, December 31, 2012	$	1,730,044		$	605,516		$	2,335,560
Issuance of convertible debt and warrants		762,111			929,156			1,691,267
Initial value of instruments in excess of face value of debt		(306,640	)		(447,376	)		(754,016	)
Change in estimated fair value		450,341			665,678			1,116,019
Balance, March 31, 2013	$	2,635,856		$	1,752,974		$	4,388,830

Management used the following inputs to value the Derivative and Warrant Liabilities for the three-months ended March 31, 2013:

	Derivative Liability	Warrant Liability
Exercise Price	$0.0573 - $0.099	$0.075 - $0.1287
Risk Free rate	.11% - .14%	.77% - .88%
Expected Volatility	192.6% - 201.0%	173.1% - 177.6%
Expected Dividend Yield	-	-

In computing the fair value of the derivative and warrant liability at March 31, 2013 for instruments under the Binomial Lattice option-pricing model, management assumed between a 80% and 95% probability of a down round financing event at various assumed stock prices of between $0.039 and $0.030. On average, a 10% change in the probability of a down round financing event would change the recorded derivative liability by approximately 7%. 

6. Contingencies

None

7. Subsequent Events

Series C Convertible Preferred Stock

In April 2013, a shareholder converted 500,000 shares of Series C Convertible Preferred stock into 500,000 shares of restricted common stock.

Common Stock

In April 2013, holders of Convertible Debentures with a face value of $90,854 converted their Convertible Debentures into 1,585,581 shares of restricted common stock. In addition, associated with these Convertible Debentures, the Company paid $749 in accrued interest by issuing 13,064 shares of common stock.

14

Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This quarterly report on Form 10-Q (the “Report”) contains forward-looking statements that are not related to historical results, including, without limitation, statements regarding our business strategy and objectives, our anticipated duration of periods of net loss, our near term operating goals, our expectations regarding the market for our products, the introduction of our products in new international markets and our beliefs with respect to opportunities and industry conditions in those markets, our beliefs about our products, product development, acquisition or licensing of complementary technologies and expectations with respect to our products’ performance and acceptance, the results of and our intentions with respect to our distribution agreement with PENTAX Europe GmbH, our beliefs about the strengths of our intellectual property portfolio, our regulatory goals and developments, anticipated clinical trials and research, our agreement with Laidlaw and its effect on our future capital resources and future financial position, our expectations with respect to stock option expense recognition, our future cash needs, the sufficiency of our working capital and our operating losses for the remainder of the current fiscal year. Although we believe that the assumptions on which these forward-looking statements are based are reasonable, there can be no assurance that such assumptions will prove to be accurate and actual results could differ materially from those discussed in the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause or contribute to such differences, including, but not limited to, changes in law or regulatory policies, unanticipated competition from other similar businesses, adverse outcomes from litigation, unexpected employee departures or disruptions, adverse market and general economic factors and other factors described in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2012. Such forward-looking statements are qualified in their entirety by the cautions and risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012.

Business

SpectraScience, Inc. (the “Company,” “SpectraScience,” “we,” “our,” or “us”) develops and manufactures innovative Laser Induced Fluorescence spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without removing tissue from the body. The WavSTAT Optical Biopsy System (the “WavSTAT System”) is SpectraScience's first product to incorporate its proprietary fluorescence technology for clinical use. The WavSTAT System carries the CE mark designation which allows for the sale and marketing in the European Union for the diagnosis of cancer. We are developing light-based diagnostics for additional indications including inflammatory bowel disease and esophageal cancer. Once these additional applications are developed we plan to self-certify for CE mark approval for sale in the European Union and then file an application with the FDA seeking permission to begin marketing for that indication for use in the United States. We believe we have a strong intellectual property portfolio that will allow us to continue to expand our WavSTAT cancer diagnosis platform to address the diagnosis of multiple cancers, utilize additional proprietary bio-photonic techniques to improve the WavSTAT’s overall diagnostic performance and ultimately allow for the detection of cancer and pre-cancer over a relatively large area of examined tissue.

Our principal executive offices are located at 11568 Sorrento Valley Rd., Suite 11, San Diego, CA 92121. We can be reached by telephone at (858) 847-0200; by fax at (858) 847-0880; or by email at info@spectrascience.com. We have a Web site at http://www.spectrascience.com. The information contained on our Web site shall not be deemed to be a part of this Report.

Plan of Operation

During the three months ended March 31, 2013, SpectraScience carried forward on the improvements made to the WavSTAT4 in fiscal 2012 and continued working with PENTAX Europe, GmbH (“PENTAX”), for distribution of its products in Europe, the Middle East and Africa.

Over the next 12 months, SpectraScience intends to:

· Market and sell the WavSTAT4 Optical Biopsy System colon cancer diagnostic application through PENTAX in the European Union;

· Conduct country-specific evaluation trials to demonstrate the effectiveness and cost benefit of the WavSTAT4 Optical Biopsy System in each relevant European jurisdiction;

· Coordinate the creation and publication of scientific papers and presentations related to the country-specific evaluation trials to support widespread education and adoption of the WavSTAT4 ;

· Pursue the introduction of the WavSTAT4 colon cancer application in other international markets, in particular Russia and India;

· Begin meeting with the FDA towards the preparation and submission of a Supplemental PMA filing with the FDA for the WavSTAT4 and plan for additional clinical trials to support eventual approval for sale in the United States;

15

· Begin the design and planning for the next generation of multi-modal fluorescence and broadband spectroscopy systems at our facility in San Diego, California; and

· Continue to expand and refine our intellectual property portfolio.

Results of Operations

Comparison of the Three Months Ended March 31, 2013 and 2012

The Company recognized no revenue for the three months ended March 31, 2013 and 2012.

Total operating expenses decreased from approximately $1,037,000 to $762,000, a decrease of approximately $275,000 for the three-month period ended March 31, 2013 as compared to the three-month period ended March 31, 2012. This overall decrease was comprised of approximate decreases in research and development expense of $193,000, general and administration expense of $50,000 and sales and marketing expense of $32,000.

Research and development expenses for the three months ended March 31, 2013 and 2012 were approximately $187,000 and $380,000, respectively. The approximate $193,000 decrease for the three months ended March 31, 2013 compared to the three months ended March 31, 2012 was due to approximate decreases in engineering development expense of $135,000, clinical studies expense of $65,000, travel expense of $10,000, offset by increases in payroll expense of approximately $11,000 and other expense of $6,000. The decrease in engineering development expense reflected the increased expense in the prior period as a result of the re-engineering of the WavSTAT4 System. The decrease in clinical studies was a result of no clinical studies in Europe in the three-month period ended March 31, 2013 as compared to several clinical studies in the same period one year ago.

General and administrative expenses for the three months ended March 31, 2013 and 2012 were approximately $498,000 and $548,000, respectively. The approximate $50,000 decrease for the three months ended March 31, 2013 compared to the three months ended March 31, 2012 was due to approximate decreases in payroll expense of $27,000, depreciation expense of $16,000, amortization expense of $13,000, investor relations expense of $10,000, travel expense of $9,000, accounting expense of $9,000 and other expense of $5,000, offset by approximate increases in investor relations consulting expense of $23,000 and stock compensation expense of $16,000. These expense decreases were a result of overall expense reductions due to cash availability constraints.

Sales and marketing expenses for the three months ended March 31, 2013 and 2012 were approximately $77,000 and $109,000, respectively. The decrease of approximately $32,000 was due to approximate decreases of $20,000 in stock compensation expense, $17,000 in travel expense, $7,000 in delivery expense, $7,000 in consulting expense and $1,000 in all other expenses offset by an approximate increase of $20,000 in payroll expense. The overall decreases were primarily a result of replacing a U.S.-based sales director with a Belgian-based sales director.

As a result of the above, the approximate net operating loss for the three months ended March 31, 2013 and 2012 was $762,000 and $1,037,000 respectively.  Of the net operating loss for the quarter ended March 31, 2013, approximately $101,000 was comprised of non-cash stock option expense.

Non-operating expense decreased approximately $254,000 as a result of non-cash income and expense related to our convertible debt issuance comprised of approximate decreases in the fair value of warrant and derivative liabilities of $466,000 offset by increases in amortization of derivative and warrant liability discount of approximately $113,000, increased amortization of debt issuance costs and original issue discount of approximately $47,000, loss on extinguishment of debt of $31,000, increased interest expense of approximately $19,000 and increases in other non-operating expense of approximately $2,000.

As a result of the above, the approximate net loss decreased by $529,000 for the three months ended March 31, 2013 compared to March 31, 2012 from approximately ($3,152,000) to ($2,623,000).  

Liquidity and Capital Resources

Historically, our sources of cash have come from the issuance and sales of equity securities, convertible debentures, interest income and limited sales of our products. Our historical cash outflows have been primarily used for operating activities including research, development, administrative and sales activities. Fluctuations in our working capital due to timing differences of cash receipts and cash disbursements also impact cash flow. We expect to incur significant additional operating losses through at least the end of 2013, as we complete proof-of-concept trials, conduct outcome-based clinical studies and increase sales and marketing efforts to commercialize the WavSTAT4 Systems in Europe. If we do not receive sufficient funding, we may be unable to continue as a going concern. We may incur unknown expenses or may not be able to meet our revenue forecast, and one or more of these circumstances would require us to seek additional capital. We may not be able to obtain equity capital or debt funding on terms that are acceptable. Even if we receive additional funding, such proceeds may not be sufficient to allow us to sustain operations until we become profitable and begin to generate positive cash flows from operations.

16

As of March 31, 2013, we had a working capital deficit of approximately $5.6 million and cash of approximately $237,000, compared to a working capital deficit of approximately $3.3 million and cash of approximately $90,000 as of December 31, 2012. In December 2011, we entered into an Engagement Agreement with Laidlaw & Company (UK) Ltd., which Engagement Agreement was amended in July 2012. Under the Engagement Agreement, Laidlaw agreed to assist us in raising up to $20.0 million in capital over a two-year period from the date of the Engagement Agreement. During the fiscal quarter ended March 31, 2013, we raised approximately $654,000, net of transaction costs, under this agreement. However, if we do not receive additional funds in a timely manner, we could be in jeopardy as a going concern. We may not be able to find alternative capital or raise capital or debt on terms that are acceptable. Management believes that if the events defined in the Engagement Agreement occur as expected, such proceeds will be sufficient to allow us to sustain operations until we attain profitability and positive cash flows from operations. However, we may incur unknown expenses or may not be able to meet our revenue expectations requiring us to seek additional capital. In such event, we may not be able to find capital or raise capital or debt on terms that are acceptable.

Since December 31, 2012, our net working capital deficit has increased from approximately $3,300,000 to $5,600,000. The primary cause of this increase in the deficit is a result of the accounting treatment required for the Convertible Debentures and warrants issued over the past twelve months. We have paid principal and interest on the Convertible Debentures that have converted by issuing shares of common stock. At March 31, 2013, adjusting for the non-cash effect of the Convertible Debentures on our net working capital deficit, the adjusted net working capital deficit would have been approximately ($494,000).

We paid principal and interest owing on Convertible Debentures that have been converted by issuing shares of common stock. The holders of Convertible Debentures control the conversion of the Convertible Debentures and certain of the Convertible Debentures were not converted at their maturity constituting a potential default on these remaining matured, but unconverted, Convertible Debentures. The holders of these unconverted Convertible Debentures have the option to declare their Convertible Debentures in default. In the event of such default, principal, accrued interest and other related costs are immediately due and payable in cash.

During the three months ended March 31, 2013, Convertible Debentures with a face value of approximately $479,000 held by thirteen individual investors matured. These remain outstanding, but none of these thirteen investors have served notice of default on the Convertible Debentures held by them.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of the end of the period covered by this Report (the “Evaluation Date”).  Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of the Evaluation Date.

Changes in Internal Financial Controls

There was no change in the Company’s internal control over financial reporting that occurred during the Company’s most recently completed quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

17

PART II OTHER INFORMATION

Item 1. Legal Proceedings

None

Item 1A. Risk Factors

There have been no material changes in our risk factors from those disclosed in Part I, Item 1A, of our Annual Report on Form 10-K for the fiscal year ended December 31, 2012.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In January 2013, the Company issued 3,000,000 shares of restricted common stock to two vendors for services. The issuance of the shares was exempt from registration by virtue of section 4(2) of the Securities Act as an issuance not involving a public offering.

During the quarter ended March 31, 2013, the Company issued an aggregate of 2,424,900 shares of common stock pursuant to the conversion by purchasers of 5% Original Issue Discount Unsecured Convertible Debentures with a conversion price equal to $0.0573 per share. The issuance of the shares was exempt from registration by virtue of Section 3(a)(9) of the Securities Act.

Item 3. Defaults Upon Senior Securities

As of May 13, 2013 there are 5% Original Issue Discount Unsecured Convertible Debentures with a face value of approximately $479,000 held by thirteen individual Holders in default. As a result, the outstanding principal amount of these Debentures, plus accrued but unpaid interest, liquidated damages and other amounts owing (estimated to be approximately $23,000) shall become immediately due and payable in cash at the election of the Holders. As of May 13, 2013, none of the Holders of these Debentures have elected to provide notice of default.

Item 4. Mine Safety Disclosures

None

Item 5. Other Information

None

Item 6. Exhibits

31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	Financial statements from the quarterly report on Form 10-Q of the Company for the quarter ended March 31, 2013, formatted in XBRL; (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statement of Shareholders’ Equity, (iv) the Consolidated Statements of Cash Flows, and (v) the Notes to the Consolidated Financial Statements.

18

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SpectraScience, Inc. (Registrant)
Date: May 20, 2013		/s/ Michael P. Oliver
		Michael P. Oliver
		President and Chief Executive Officer
		(Principal executive officer)
Date: May 20, 2013		/s/ James Dorst
		James Dorst
		Chief Financial Officer and Chief Operating Officer
		(Principal financial officer and principal accounting officer)

19

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael P. Oliver, certify that:

1. I have reviewed this quarterly report on Form 10-Q of SpectraScience, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Michael P. Oliver

Name: Michael P. Oliver

Title: Chief Executive Officer

Date:    May 20, 2013

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, James Dorst, certify that:

1. I have reviewed this quarterly report on Form 10-Q of SpectraScience, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ James Dorst

Name: James Dorst

Title: Chief Financial Officer

Date:  May 20, 2013

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of SpectraScience, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael P. Oliver, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Michael P. Oliver

Michael P. Oliver

Chief Executive Officer

Date: May 20, 2013

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of SpectraScience, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James Dorst, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ James Dorst

James Dorst

Chief Financial Officer

Date: May 20, 2013

XML

Shareholders' Equity - Additional Information (Detail) (USD $)	3 Months Ended		1 Months Ended	3 Months Ended	1 Months Ended
	Mar. 31, 2013	Mar. 31, 2013 Five Year Warrants	Jan. 31, 2013 Restricted Stock	Mar. 31, 2013 Agent Five Year Warrants	Feb. 28, 2013 Convertible Debentures
Stockholders Equity Note [Line Items]
Debt instrument, face amount	$ 854,737				$ 126,316
Debt Instrument, Convertible, Number of Equity Instruments					2,204,453
Accrued interest related to debentures					12,632
Debt Instrument Convertible Interest Expense Number Of Equity Instruments issued					220,447
Common Stock issued for services (in shares)			3,000,000
Common Stock issued for services	$ 55,149
Warrants Issued To Purchase Common Stock		7,458,437
Warrants Issued As Compensation				2,237,531
Warrants Exercise Price One		$ 0.0745
Warrants Maturity Period	five-year

XML

Liabilities

3 Months Ended

Mar. 31, 2013

Liabilities [Abstract]

Liabilities

3. Liabilities

Convertible Debentures

For the three-month period ended March 31, 2013, the Company issued Convertible Debentures (“Debentures”) at a face amount of $854,737. At March 31, 2013, the unamortized discount of $886,241 consisted of a discount on the derivative liability of $495,203, discount on the warrant liability of $345,596 and original issue discount of $45,442. The discounts will be amortized over the remaining term of the Debentures. The Debentures have an original term of six months, accrue interest at rates ranging from 16-20% per year, carry an original issue discount of 5% and will convert into common stock at an initial conversion price ranging from $0.0573 to $0.099 per share at maturity. The Debentures were issued with detachable five-year cashless warrants (“Holders Warrants”) that allow the holders to purchase one share of stock for each two shares available under the converted Debentures at an exercise price ranging from $0.0745 to $0.1287 per share. In addition, the Company issued five-year cashless Agent Warrants equal to 10% of the total number of shares issuable under the Debentures and Holders Warrants at an exercise price ranging from $0.0745 to $0.1287 per share. At March 31, 2013, there were Debentures, Holders Warrants and Agent Warrants convertible or exercisable into 27,796,733, 34,409,070 and 9,824,338 shares of common stock, respectively. The conversion price of the Debentures and Holders Warrants are subject to an adjustment feature in the event that the Company issues securities for less than the conversion price of the Debentures. The Holders and Agent Warrants contain a provision under which the Warrants, under certain circumstances, could be acquired for a presently undetermined consideration at a future date. The accounting for the adjustment features of the conversion price for the debt and the warrant exercise price for the Holders’ Warrants is described separately below under, “Warrant Liability” and “Derivative Liability”. For the three-month period ended March 31, 2013, upon issuance of the Debentures the Company received net cash proceeds of $653,560, net of $158,440 in transaction costs and $42,737 of original issue discount. For the three-month period ended March 31, 2013, Debentures with a face value of $126,316 and accrued interest of $12,632 were converted at a price of $0.0573 into 2,424,900 shares of common stock. At March 31, 2013, Debentures with a face value of approximately $479,000 were in default and accruing interest at a default rate of 20% per year.

Warrant Liability

The Company issued Convertible Debentures, which included Holders Warrants (“Securities”). In addition, the Company issued Agent warrants to Laidlaw & Co. Ltd. as compensation related to the sale of the Securities. The Holders Warrants include a possible adjustment feature in the event of a future financing on terms more favorable than those of the existing Securities. Additionally, the Holders and Agent Warrants also contain a provision that provides for specific consideration in the event of certain all cash or private change of control transactions. This results in the Holders and Agent Warrants being classified as “Derivative Warrants”. The accounting guidance requires that these warrants be recorded as a liability and measured at fair value on a recurring basis. The Company records the fair value of these warrants in its statement of operations in the line “Change in fair value of derivative liabilities.” The Company measures these warrants using a combination of Black-Scholes option valuation models and Binomial Lattice option valuation models using similar assumptions to those described under “Stock-Based Compensation.” At March 31, 2013, there were exercisable warrants to purchase 44,233,408 shares of common stock. The time period over which the Company will be required to evaluate the fair value of these warrants is approximately five years. For the three-month period ended March 31, 2013, upon issuance of the Debentures, the Company recorded an additional Warrant Liability of $762,111 of which $306,640 was recognized as an immediate non-cash expense and the remaining amount is being amortized over the life of the associated Debentures (generally, six-months).

The Company computes the fair value of the warrant liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the warrant liability is the Company’s stock price, which is subject to significant fluctuation and is not under the Company’s control. The resulting effect on the Company’s net loss is therefore subject to significant fluctuation and will continue to be so until the Derivative Warrants expire (approximately five years from the date of issuance). Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.

The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment of the probability of a more favorably priced future financing or significant fluctuations in the volatility of the trading market for the Company’s common stock the Company’s fair value estimates could be materially different in the future.

Derivative Liability

During the three-month period ended March 31, 2013, the Company issued convertible Debentures with a conversion price that includes a possible exercise adjustment feature in the event that it issues securities for consideration less than that offered with the convertible Debentures (referred to as “Derivative Liabilities”). The Company records the fair value of the conversion feature in its statement of operations in the line “Change in fair value of derivative liabilities.” The Company measures the conversion feature using a Binomial Lattice option valuation model using similar assumptions to those described under “Stock-Based Compensation.” At March 31, 2013, there were convertible shares to purchase 27,796,733 shares of common stock subject to this price adjustment feature. The time period over which the Company will be required to evaluate the fair value of this conversion feature is the lesser of six months or conversion. For the three-month period ended March 31, 2013, upon issuance of the Debentures, the Company recorded a derivative liability of $929,156 and an initial fair value non-cash expense of $447,376. Convertible Debentures with a face value of $126,316 converted into approximately 2,425,000 shares of Common Stock.

The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Debentures, which the convertible feature is associated with, mature. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.

The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, the Company’s fair value estimates could be materially different in the future.

XML

Derivative and Warrant Liabilities (Detail) (USD $)	3 Months Ended
	Mar. 31, 2013
Derivative
Derivative and Warrant Liabilities Disclosure [Line Items]
Expected Dividend Yield	0.00%
Derivative | Maximum
Derivative and Warrant Liabilities Disclosure [Line Items]
Exercise Price	0.099
Risk Free rate	0.14%
Expected Volatility	201.00%
Derivative | Minimum
Derivative and Warrant Liabilities Disclosure [Line Items]
Exercise Price	0.0573
Risk Free rate	0.11%
Expected Volatility	192.60%
Warrant
Derivative and Warrant Liabilities Disclosure [Line Items]
Expected Dividend Yield	0.00%
Warrant | Maximum
Derivative and Warrant Liabilities Disclosure [Line Items]
Exercise Price	0.1287
Risk Free rate	0.88%
Expected Volatility	177.60%
Warrant | Minimum
Derivative and Warrant Liabilities Disclosure [Line Items]
Exercise Price	0.075
Risk Free rate	0.77%
Expected Volatility	173.10%

XML

Changes in Liabilities with Significant Unobservable Inputs (Level 3) (Detail) (USD $)	3 Months Ended
	Mar. 31, 2013
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, December 31, 2012	$ 2,335,560
Issuance of convertible debt and warrants	1,691,267
Initial value of instruments in excess of face value of debt	(754,016)
Change in estimated fair value	1,116,019
Balance, March 31, 2013	4,388,830
Warrant Liability
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, December 31, 2012	1,730,044
Issuance of convertible debt and warrants	762,111
Initial value of instruments in excess of face value of debt	(306,640)
Change in estimated fair value	450,341
Balance, March 31, 2013	2,635,856
Derivative Liabilities
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance, December 31, 2012	605,516
Issuance of convertible debt and warrants	929,156
Initial value of instruments in excess of face value of debt	(447,376)
Change in estimated fair value	665,678
Balance, March 31, 2013	$ 1,752,974

XML

Subsequent Events - Additional Information (Detail) (USD $)			1 Months Ended
	Mar. 31, 2013	Dec. 31, 2012	Apr. 30, 2013 Subsequent Event
Subsequent Event [Line Items]
Convertible debt, net	$ 971,653	$ 608,622	$ 90,854
Accrued interest related to debentures			749
Issuance Of Common Stock For Accrued Interest Shares			13,064
Convertible preferred stock shares issued upon conversion			500,000
Preferred stock converted into restricted common stock			500,000
Debt conversion converted instrument amount 1			$ 1,585,581

XML

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2013

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.     Summary of Significant Accounting Policies

Revenue recognition

The Company recognizes revenues when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue from the sale of the Company’s products is generally recognized when title and risk of loss transfers to the customer, the terms of which are generally free on board shipping point. The Company uses customer purchase orders to determine the existence of an arrangement. The Company uses shipping documents and third-party proof of delivery to verify that title has transferred. The Company assesses whether the price is fixed or determinable based upon the terms of the agreement associated with the transaction. To determine whether collection is probable, the Company assesses a number of factors, including past transaction history with the customer and the creditworthiness of the customer.

Consolidation

The accompanying consolidated financial statements include the accounts of SpectraScience, Inc. and its wholly-owned subsidiaries LUMA, and International. All significant intercompany balances and transactions have been eliminated in consolidation.

Risks and Uncertainties

The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. The Company's operations are subject to significant risk and uncertainties, including financial, operational, technological, regulatory and other risks associated with a short history of product sales, including the potential risk of business failure.

Use of Estimates

The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Significant estimates made by management include, among others, realization of long-lived assets including intangible assets, assumptions used to value stock options, assumptions used to value the common stock issued and assumptions related to the determination of the fair value of the derivative components associated with the Company’s Convertible Debentures. Actual results could differ from those estimates.

Inventory Valuation

The Company records its inventories at the lower of cost or market value, determined on a specific cost basis. The Company provides inventory allowances when conditions indicate that the selling price could be less than cost due to obsolescence and reductions in estimated future demand. The Company balances the need to maintain strategic inventory levels with the risk of obsolescence due to changing technology and customer demand levels. Unfavorable changes in market conditions may result in a need for additional inventory reserves that could adversely impact the Company’s gross margins. Conversely, favorable changes in demand could result in higher gross margins when the Company sells products.

Valuation of Long-lived Assets

The Company’s long-lived assets consist of fixed assets and intangible assets. Equipment is carried at cost and is depreciated over the estimated useful lives of the assets, which are generally two to three years, and leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the improvements. The straight-line method is used for depreciation and amortization. Intangible assets consist of patents, which are amortized using the straight-line method over the estimated useful lives of the patents. The Company does not capitalize external legal costs and filing fees associated with obtaining patents on its new discoveries. Acquired intellectual property is recorded at fair value and is amortized over its estimated useful life. The Company believes the useful lives assigned to these assets are reasonable. The Company assesses the recoverability of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. These computations utilize judgments and assumptions inherent in management’s estimate of future cash flows to determine recoverability of these assets. If management’s assumptions about these assets were to change as a result of events or circumstances, the Company may be required to record an impairment loss.  

Convertible Debentures/Warrants

We account for our Convertible Debentures, associated warrants and related conversion features under the provisions of FASB Topic 470, Debt, or ASC 470, which requires the measurement and recognition of the fair values for all components related to the Convertible Debentures at the end of each reporting period. We estimate the fair value of the resulting Beneficial Conversion Feature ("BCF"), holders warrants and agent warrants at each measurement date using a combination of the Black-Scholes-Merton and modified Binomial Lattice option-pricing models. These standards require us to record the fair value of the Convertible Debentures, BCF and warrants at the time of issuance and to remeasure these values and record associated income statement expense or benefit at the end of each reporting period.

Stock-Based Compensation

The Company accounts for stock-based compensation under the provisions of FASB ASC Topic 718, Compensation—Stock Compensation   (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company adopted ASC 718 on January 1, 2006. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes-Merton option-pricing model (the “Black-Scholes Model”). The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. The Company estimates forfeitures at the time of grant and revises its estimate in subsequent periods if actual forfeitures differ from those estimates.

The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC Topic 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.

All issuances of stock options or other equity instruments to employees and non-employees as the consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Any stock options issued to non-employees are recorded in expense and additional paid-in capital in shareholders’ equity over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options at the end of each reporting period.

As of March 31, 2013, the Company had one stock-based employee compensation plan under which it makes grants, the 2011 Equity Incentive Plan (the “EIP”). The EIP provides for the grant of incentive stock options (“ISOs”), nonqualified stock options (“NQSOs”) and restricted stock awards to full-time employees (who may also be directors) and NQSOs and restricted stock awards to non-employee directors, consultants, customers, vendors or providers of services. The exercise price of any ISO may not be less than the fair market value of the common stock on the date of grant and the term shall not exceed ten years. The amount reserved under the 2011 EIP is 15,000,000 shares of common stock.  At March 31, 2013, the Company had outstanding 19,491,667 options under the EIP and the Company’s prior Amended 2001 Stock Plan representing approximately 13% of the Company’s outstanding shares (10,141,979 of which were exercisable), with 6,453,333 available for future issuance under the 2011 EIP. Awards under the Company’s EIP generally vest over four years.

The fair value of options granted were estimated at the date of grant using a Black-Scholes Model which includes several variables including expected life, risk free interest rate, expected stock price volatility, stock option exercise patterns and expected dividend yield. The Company also must estimate forfeitures for employee stock options. These models and assumptions are complex and may change future expenses by increasing or decreasing stock-based compensation expense. There were no stock options granted during the three month period ended March 31, 2013. Management used the following weighted average assumptions to value stock options granted during the three months ended March 31, 2013 and 2012:

	2013		2012
Expected life	-		5 Years
Risk-free interest rate		-		.85	%
Expected volatility		-		113	%
Expected dividend yield		-		0	%

Management believes estimated forfeitures for employee stock options granted under the EIP would have a negligible effect on expenses because such forfeitures would be a very small percentage. Stock option grants have been to a group of individuals that have a high desire to see the Company succeed and have aligned themselves to that end.  

The expected lives used in the calculations were selected by management based on past experience, forward looking profit forecasts and estimates of what the trading price of the Company’s stock might be at different future dates.

The risk-free interest rates used in the calculations are the five-year U.S. Treasury rates as published on the date of the applicable stock option grant.

Volatility is a calculation based on fluctuations in the Company’s stock price over a historical time period consistent with the estimated life of the option.

Options outstanding that have vested and those that remain unvested as of March 31, 2013 are as follows:

			Weighted		Weighted Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual Term in		Intrinsic
	Shares		Price		Years		Value(1)
Vested		10,414,979	$	0.23		6.56	$	-
Unvested		9,349,688		0.13		8.69		-
Total		19,491,667	$	0.18		7.58	$	-

(1) These amounts represent the excess, if any, between the exercise price and $0.05, the closing market price of the Company’s common stock on March 31, 2013 as quoted on the Over-the-Counter Bulletin Board under the symbol “SCIE”.

Additional information with respect to stock option activity is as follows: 

			Outstanding Options
	Options Available For Grant		Plan Options Outstanding		Weighted Average Exercise Price Per Share		Weighted-Average Remaining Contractual  Term (years)		Aggregate Intrinsic Value
December 31, 2012		6,453,333		19,491,667	$	0.18		8.20		-
Options granted		-		-		-		-		-
Options exercised		-		-		-		-		-
Options forfeited		-		-		-		-		-
Additional options authorized		-		-		-		-		-
Outstanding at March 31, 2013		6,453,333		19,491,667	$	0.18		7.58		-
Exercisable at March 31, 2013		-		10,141,979	$	0.23		6.56		-

There were no options exercised during the three months ended March 31, 2013 and 2012. At March 31, 2013, total unrecognized estimated employee compensation cost related to non-vested stock options granted prior to that date is approximately $739,000, which is expected to be recognized over the next four years.

Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share is computed similarly to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and only if the additional common shares would be dilutive. Potentially dilutive shares of common stock that have been excluded from the calculation of the weighted average number of dilutive common shares for the three-months ended March 31, 2013 include common stock purchase warrants to acquire 70,210,121 shares of common stock, stock options to purchase 19,491,667 shares of common stock and preferred stock convertible into 3,585,000 shares of common stock.

The following table sets forth the computation of basic and diluted earnings per share and incorporates any additional income related to the change in fair value of derivative securities for the three-month period ending March 31, 2013:

	For the Three			For the Three
	Months Ended			Months Ended
	March 31,			March 31,
	2013			2012
Numerator:
Net (loss) for basic earning per share		(2,623,096	)		(3,152,001	)
Subtractions:
Change in fair value of derivative securities		-			-
Net (loss) for diluted earnings per share		(2,623,096	)		(3,152,001	)
Denominator:
Weighted average basic shares outstanding		155,871,102			108,041,084
Assumed conversion of dilutive securities
Warrants		-			-
Conversion feature - Convertible Debentures		-			-
Potentially dilutive common shares		-			-
Denominator for diluted earnings per share - Adjusted weighted average shares		155,871,102			108,041,084
(Loss) per share
Basic	$	(0.02	)	$	(0.03	)
Diluted	$	(0.02	)	$	(0.03	)

Inventories

Inventories consisted of the following at March 31, 2013 and December 31, 2012:

	March 31, 2013		December 31, 2012
Raw materials	$	158,420	$	155,022
Finished goods		47,055		47,055
Totals	$	205,475	$	202,077

XML

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2013	Dec. 31, 2012
Current assets:
Cash	$ 237,162	$ 90,192
Inventories	205,475	202,077
Deferred debt issuance costs	284,050	165,649
Prepaid expenses and other current assets	175,212	191,030
Total current assets	901,899	648,948
Fixed assets, net	67,151	85,592
Patents, net	1,637,425	1,678,787
TOTAL ASSETS	2,606,475	2,413,327
Current liabilities:
Accounts payable	897,279	861,698
Convertible debt	1,857,894	1,129,473
Discount	(886,241)	(520,851)
Convertible debt, net	971,653	608,622
Derivative liability	4,388,830	2,335,560
Accrued expenses	214,677	183,855
Total current liabilities	6,472,439	3,989,735
COMMITMENTS
SHAREHOLDERS' EQUITY (DEFICIT)
Common stock, $.01 par value: Authorized - 275,000,000 shares; Issued and outstanding -157,654,565 shares at March 31, 2013 and 152,229,665 shares at December 31, 2012	1,576,546	1,522,297
Additional paid-in capital	35,770,894	35,491,603
Accumulated deficit	(41,249,254)	(38,626,158)
TOTAL SHAREHOLDERS' (DEFICIT)	(3,865,964)	(1,576,408)
TOTAL LIABILITIES AND SHAREHOLDERS' (DEFICIT)	2,606,475	2,413,327
Series B Convertible Preferred Stock
SHAREHOLDERS' EQUITY (DEFICIT)
Convertible Preferred Stock, value	25,850	25,850
Series C Convertible Preferred Stock
SHAREHOLDERS' EQUITY (DEFICIT)
Convertible Preferred Stock, value	$ 10,000	$ 10,000

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
OPERATING ACTIVITIES:
Net loss	$ (2,623,096)	$ (3,152,001)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	59,803	88,906
Amortization of derivative and warrant liabilities discount	464,068	351,425
Amortization of deferred debt issuance costs and original issue discount	190,569	143,571
Change in fair value of derivative and warrant liabilities	1,116,019	1,582,406
Loss on extinguishment of debt	30,796	0
Fair market value of common stock issued for services	55,149	0
Changes in operating assets and liabilities:
Accounts receivable	0	0
Inventories	(3,398)	(76,932)
Prepaid expenses and current other assets	15,818	(2,050)
Accounts payable	35,581	(99,833)
Accrued expenses	50,413	(30,288)
Net cash (used in) operating activities	(506,590)	(1,095,218)
INVESTING ACTIVITIES:
Purchases of fixed assets	0	(4,170)
Net cash from (used in) investing activities	0	(4,170)
FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes payable	812,000	2,233,000
Debt issuance costs	(158,440)	(379,402)
Net cash provided by financing activities	653,560	1,853,598
Net increase in cash	146,970	754,210
CASH AT BEGINNING OF PERIOD	90,192	250,723
CASH AT END OF PERIOD	237,162	1,004,933
NON CASH INVESTING AND FINANCING ACTIVITIES
Convertible debt and accrued interest converted to common stock	138,948	0
Convertible debt and warrant liability discounts recorded at issuance	812,000	2,212,928
Deferred debt issuance costs recorded at issuance	125,251	435,788
Employees
Adjustments to reconcile net loss to cash used in operating activities:
Stock-based compensation	99,642	92,457
Consultants
Adjustments to reconcile net loss to cash used in operating activities:
Stock-based compensation	$ 2,106	$ 7,121

XML

Summary Basic and Diluted Earnings Per Share and Additional Income (Detail) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Numerator:
Net (loss) for basic earning per share	$ (2,623,096)	$ (3,152,001)
Subtractions:
Change in fair value of derivative securities	0	0
Net (loss) for diluted earnings per share	(2,623,096)	(3,152,001)
Denominator:
Weighted average basic shares outstanding	155,871,102	108,041,084
Assumed conversion of dilutive securities
Warrants	0	0
Conversion feature - Convertible Debentures	0	0
Potentially dilutive common shares	$ 0	$ 0
Denominator for diluted earnings per share - Adjusted weighted average shares	155,871,102	108,041,084
(Loss) per share
Basic	$ (0.02)	$ (0.03)
Diluted	$ (0.02)	$ (0.03)

XML

Liabilities - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012
Debt Instrument [Line Items]
Unamortized discount	$ 886,241		$ 520,851
Original issue discount, percent	5.00%
Securities convertible or exercisable into shares	27,796,733
Proceeds from issuance of debentures	653,560
Debt issuance costs	158,440	379,402
Original issue discount	42,737
Exercisable warrants to purchase shares of common stock	44,233,408
Fair value estimate of warrants	5 years
Derivative warrants expiration period	5 years
Debt instrument, face amount	854,737
Proceeds from issuance of convertible notes payable	812,000	2,233,000
Derivative Financial Instruments, Liabilities
Debt Instrument [Line Items]
Unamortized discount	495,203
Warrant Liability
Debt Instrument [Line Items]
Unamortized discount	345,596
Original Discount
Debt Instrument [Line Items]
Unamortized discount	45,442
Holders Warrants
Debt Instrument [Line Items]
Securities convertible or exercisable into shares	34,409,070
Agents Warrants
Debt Instrument [Line Items]
Securities convertible or exercisable into shares	9,824,338
Convertible Debentures
Debt Instrument [Line Items]
Securities convertible or exercisable into shares	27,796,733
Non-cash expense related to convertible debentures	447,376
Issuance of Debentures
Debt Instrument [Line Items]
Non-cash expense related to warrants	306,640
Warrant liability	762,111
Derivative liability	929,156
Debentures One
Debt Instrument [Line Items]
Accrued interest rate per year	20.00%
Conversion price at maturity	$ 0.0573
Debt Instrument, Convertible, If-converted Value in Excess of Principal	126,316
Interest Payable	12,632
Debt Instrument, Convertible, Number of Equity Instruments	2,424,900
Debt instrument, face amount	$ 479,000
Debentures Two
Debt Instrument [Line Items]
Debt Instrument, Convertible, Number of Equity Instruments	2,425,000
Minimum
Debt Instrument [Line Items]
Debentures payment term	6 months
Accrued interest rate per year	16.00%
Conversion price at maturity	$ 0.0573
Convertible Debentures exercise price	$ 0.0745
Maximum
Debt Instrument [Line Items]
Accrued interest rate per year	20.00%
Conversion price at maturity	$ 0.099
Convertible Debentures exercise price	$ 0.1287

XML

Nature of Business and Basis of Presentation

3 Months Ended

Mar. 31, 2013

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Nature of Business and Basis of Presentation

1.     Nature of Business and Basis of Presentation

Description of Business

SpectraScience, Inc. was incorporated in the State of Minnesota on May 4, 1983 as GV Medical, Inc. In October 1992, GV Medical discontinued its prior business, refocused its development efforts and changed its name to SpectraScience, Inc. The “Company,” hereinafter, refers to SpectraScience, Inc. and its wholly owned subsidiaries Luma Imaging Corporation (“LUMA”) and Spectra Science International, Inc. (“International”). From 1996, the Company primarily focused on developing the WavSTAT Optical Biopsy System (the “WavSTAT System”). 

The Company has developed and received the European CE mark approval to market a proprietary, minimally invasive technology that optically illuminates tissue in real-time to distinguish between normal, pre-cancerous or cancerous cells without the need to remove the subject cell tissue from the body to make such determinations. The WavSTAT System operates by using cool, safe laser light to optically illuminate and analyze tissue, enabling the physician to make an instant diagnosis during endoscopy when screening for cancer, and if warranted, to begin immediate treatment during the same procedure. Beginning in December 2011, the WavSTAT 4 version of the product began to be sold in the European Union for colon cancer detection. In June 2012, the Company entered into a distribution agreement with PENTAX Europe, GmbH, for the sale of its systems internationally.

On November 6, 2007, the Company acquired the assets of LUMA in an equity transaction accounted for as an acquisition of assets and now operates LUMA as a wholly-owned subsidiary of the Company. LUMA had acquired the assets from a predecessor company that had developed, and received FDA approval for, a non-invasive diagnostic imaging system that can detect cervical cancer precursors and which utilizes an underlying technology that is similar to that of the WavSTAT System. The addition of the LUMA technology to the Company’s existing WavSTAT System technology provides the Company with a broad suite of fluorescence-based intellectual property and know-how. During the fiscal year ended December 31, 2010, the Company wrote off the remaining fair value of the LUMA inventory in order to focus on the continued development and marketing of the WavSTAT System. The Company retained the intellectual property of LUMA for use in the development of future generations of the WavSTAT System.

The transaction was accounted for as an acquisition of assets that included intellectual property, inventory and equipment. The intellectual property consisted of a total of 34 issued U.S. patents and 28 additional patent applications.

Basis of Presentation

The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are prescribed for smaller reporting companies. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the three-month period ended March 31, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. These statements should be read in conjunction with the financial statements and related notes, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

Liquidity and Capital Resources

Historically, the Company’s sources of cash have come from the issuance and sales of equity securities, convertible debentures and interest income. The Company’s historical cash outflows have been primarily used for operating activities including research, development, administrative and sales activities. Fluctuations in the Company’s working capital due to timing differences of its cash receipts and cash disbursements also impact its cash flow. The Company expects to incur significant additional operating losses through at least the end of 2013, as it completes proof-of-concept trials, conducts outcome-based clinical studies and increases sales and marketing efforts to commercialize the WavSTAT4 Systems in Europe. If the Company does not receive sufficient funding, the Company may be unable to continue as a going concern. The Company may incur unknown expenses or may not be able to meet its revenue forecast, and one or more of these circumstances would require the Company to seek additional capital. The Company may not be able to obtain equity capital or debt funding on terms that are acceptable. Even if the Company receives additional funding, such proceeds may not be sufficient to allow the Company to sustain operations until it becomes profitable and begins to generate positive cash flows from operations.

As of March 31, 2013, the Company had a working capital deficit of approximately $5.6 million and cash of approximately $237,000, compared to working capital deficit of approximately $3.3 million and cash of approximately $90,000 as of December 31, 2012. In December 2011, the Company entered into an Engagement Agreement with Laidlaw & Company (UK) Ltd., which Engagement Agreement was amended in July 2012. Under the Engagement Agreement, Laidlaw agreed to assist the Company in raising up to $20.0 million in capital over a two year period from the date of the Engagement Agreement. During the fiscal quarter ended March 31, 2013, the Company raised approximately $654,000, net of transaction costs, under this agreement. However, if the Company does not receive additional funds in a timely manner, the Company could be in jeopardy as a going concern. The Company may not be able to find alternative capital or raise capital or debt on terms that are acceptable. Management believes that if the events defined in the Engagement Agreement occur as expected, such proceeds will be sufficient to allow the Company to sustain operations until it attains profitability and positive cash flows from operations. However, the Company may incur unknown expenses or may not be able to meet its revenue expectations requiring it to seek additional capital. In such event, the Company may not be able to find capital or raise capital or debt on terms that are acceptable.

The Company paid principal and interest owing on Convertible Debentures that have been converted by issuing shares of common stock. The holders of Convertible Debentures control the conversion of the Convertible Debentures and certain of the Convertible Debentures were not converted at their maturity constituting a potential default on these remaining matured, but unconverted, Convertible Debentures. The holders of these unconverted Convertible Debentures have the option to declare their Convertible Debentures in default. In the event of such default, principal, accrued interest and other related costs are immediately due and payable in cash.

During the three months ended March 31, 2013, Convertible Debentures with a face value of approximately $479,000 held by thirteen individual investors matured. These remain outstanding, but none of these thirteen investors have served notice of default on the Convertible Debentures held by them.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2013	Dec. 31, 2012
Common stock, par value	$ 0.01	$ 0.01
Common stock, authorized	275,000,000	275,000,000
Common stock, shares issued	157,654,565	152,229,665
Common stock, shares outstanding	157,654,565	152,229,665
Series B Convertible Preferred Stock
Convertible Preferred Stock, par value	$ 0.01	$ 0.01
Convertible Preferred Stock, authorized	2,585,000	2,585,000
Convertible Preferred Stock, shares issued	2,585,000	2,585,000
Convertible Preferred Stock, shares outstanding	2,585,000	2,585,000
Convertible Preferred Stock, liquidation value	$ 517,000	$ 517,000
Convertible Preferred Stock, accumulated and unpaid dividends	106,931	106,931
Series C Convertible Preferred Stock
Convertible Preferred Stock, par value	$ 0.01	$ 0.01
Convertible Preferred Stock, authorized	1,000,000	1,000,000
Convertible Preferred Stock, shares issued	1,000,000	1,000,000
Convertible Preferred Stock, shares outstanding	1,000,000	1,000,000
Convertible Preferred Stock, liquidation value	$ 200,000	$ 200,000

XML

Nature of Business and Basis of Presentation - Additional Information (Detail) (USD $)	3 Months Ended			3 Months Ended
	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011 Maximum	Mar. 31, 2013 Minimum
Disclosure Nature Of Business and Basis Of Presentation Additional Information [Line Items]
Working capital deficit	$ 5,600,000	$ 3,300,000
Cash and cash equivalents	237,000	90,000
Capital to be raised			20,000,000
Working capital contribution period				2 years
Capital raised during period	654,000
Conversion of stock, amount issued	$ 479,000

XML

Document and Entity Information	3 Months Ended
	Mar. 31, 2013	May 20, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q1
Trading Symbol	SCIE
Entity Registrant Name	SPECTRASCIENCE INC
Entity Central Index Key	0000727672
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock Shares Outstanding		159,253,139

XML

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2013	Dec. 31, 2012
Significant Accounting Policies [Line Items]
Options outstanding	19,491,667	19,491,667
Number of shares exercisable	10,141,979
Common stock shares available	6,453,333
Non-vested stock options period granted expected to be recognized	4 years
Closing market price per share	$ 0.05
Total unrecognized estimated employee compensation cost related to non-vested stock options granted	$ 739,000
Stock Option
Significant Accounting Policies [Line Items]
common stock purchase warrants to acquire	70,210,121
Convertible Preferred Stock
Significant Accounting Policies [Line Items]
Potentially dilutive shares of common stock excluded from calculation of weighted average number of shares	3,585,000
Equity Incentive Plan Twenty Eleven
Significant Accounting Policies [Line Items]
Shares of common stock reserved under EIP	15,000,000
Stock Plan 2001
Significant Accounting Policies [Line Items]
Options outstanding as a percentage of outstanding shares	13.00%
Non-vested stock options period granted expected to be recognized	4 years

XML

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenue	$ 0	$ 0
Cost of revenue	0	0
Gross profit	0	0
Operating expenses:
Research and development	187,457	380,286
General and administrative	497,703	547,645
Sales and marketing	77,374	108,696
Total operating expenses	762,545	1,036,627
Loss from operations	(762,545)	(1,036,627)
Other expense (income)
Interest expense	56,581	38,028
Change in fair value of derivative liabilities	1,116,019	1,582,406
Amortization of debt liability discount	464,068	351,425
Amortization of deferred debt issuance costs and ooooriginal issue discount	190,569	143,571
Loss on extinguishment of debt	30,796	0
Other expense (income), net	2,518	(56)
Nonoperating Income (Expense)	1,860,551	2,115,374
Net (Loss)	$ (2,623,096)	$ (3,152,001)
Basic and diluted net (loss) per share	$ (0.02)	$ (0.03)
Weighted average common shares outstanding - basic and diluted	155,871,102	108,041,084

XML

Contingencies

3 Months Ended

Mar. 31, 2013

Commitments and Contingencies Disclosure [Abstract]

Contingencies

6. Contingencies

None

XML

Fair Value Measurements

3 Months Ended

Mar. 31, 2013

Fair Value Measurements [Abstract]

Fair Value Measurements

5. Fair Value Measurements

Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.

The Company's balance sheet contains derivative and warrant liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:

Level 1: uses quoted market prices in active markets for identical assets or liabilities.

Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: uses unobservable inputs that are not corroborated by market data.

The fair value of the Company’s recorded derivative and warrant liabilities is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. Binomial Lattice and Black Scholes option valuation models were used to determine the fair value with similar assumptions to those described under “Stock-Based Compensation”. The Company records derivative and warrant liabilities on the consolidated balance sheets at fair value with changes in fair value recorded in the consolidated statements of operations.

The following table presents the balances of liabilities measured at fair value on a recurring basis by level as of December 31, 2012 and March 31, 2013:

	Fair Value Measurements Using
	Quoted Prices in		Significant Other		Significant
	Active Markets for		Observable		Unobservable
	Identical Assets		Inputs		Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
As of December 31, 2012
Derivative liability	$	-	$	-	$	605,516	$	605,516
Warrant liability		-		-		1,730,044		1,730,044
Total	$	-	$	-	$	2,335,560	$	2,335,560

	Fair Value Measurements Using
	Quoted Prices in		Significant Other		Significant
	Active Markets for		Observable		Unobservable
	Identical Assets		Inputs		Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
As of March 31, 2013
Derivative liability	$	-	$	-	$	1,752,974	$	1,752,974
Warrant liability		-		-		2,635,856		2,635,856
Total	$	-	$	-	$	4,388,830	$	4,388,830

The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the three months ended March 31, 2013:

	Warrant			Derivative			Total
	Liability			Liability			Liability
Balance, December 31, 2012	$	1,730,044		$	605,516		$	2,335,560
Issuance of convertible debt and warrants		762,111			929,156			1,691,267
Initial value of instruments in excess of face value of debt		(306,640	)		(447,376	)		(754,016	)
Change in estimated fair value		450,341			665,678			1,116,019
Balance, March 31, 2013	$	2,635,856		$	1,752,974		$	4,388,830

Management used the following inputs to value the Derivative and Warrant Liabilities for the three-months ended March 31, 2013:

	Derivative Liability	Warrant Liability
Exercise Price	$0.0573 - $0.099	$0.075 - $0.1287
Risk Free rate	.11% - .14%	.77% - .88%
Expected Volatility	192.6% - 201.0%	173.1% - 177.6%
Expected Dividend Yield	-	-

In computing the fair value of the derivative and warrant liability at March 31, 2013 for instruments under the Binomial Lattice option-pricing model, management assumed between a 80% and 95% probability of a down round financing event at various assumed stock prices of between $0.039 and $0.030. On average, a 10% change in the probability of a down round financing event would change the recorded derivative liability by approximately 7%.

XML

Inventories (Detail) (USD $)	Mar. 31, 2013	Dec. 31, 2012
Inventory Disclosure [Line Items]
Raw Materials	$ 158,420	$ 155,022
Finished Goods	47,055	47,055
Inventories	$ 205,475	$ 202,077

XML

Summary of Weighted Average Assumptions to Value Stock Options Granted (Detail)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	0 years	5 years
Risk-free interest rate	0.00%	0.85%
Expected volatility	0.00%	113.00%
Expected dividend yield	0.00%	0.00%

XML

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2013

Summary of Weighted Average Assumptions To Value Stock Options Granted

Management used the following weighted average assumptions to value stock options granted during the three months ended March 31, 2013 and 2012:

	2013		2012
Expected life	-		5 Years
Risk-free interest rate		-		.85	%
Expected volatility		-		113	%
Expected dividend yield		-		0	%

Schedule Of Share Based Compensation Stock Options Oustanding

Options outstanding that have vested and those that remain unvested as of March 31, 2013 are as follows:

			Weighted		Weighted Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual Term in		Intrinsic
	Shares		Price		Years		Value(1)
Vested		10,414,979	$	0.23		6.56	$	-
Unvested		9,349,688		0.13		8.69		-
Total		19,491,667	$	0.18		7.58	$	-

(1) These amounts represent the excess, if any, between the exercise price and $0.05, the closing market price of the Company’s common stock on March 31, 2013 as quoted on the Over-the-Counter Bulletin Board under the symbol “SCIE”.

Summary Stock Option Activity

Additional information with respect to stock option activity is as follows: 

			Outstanding Options
	Options Available For Grant		Plan Options Outstanding		Weighted Average Exercise Price Per Share		Weighted-Average Remaining Contractual  Term (years)		Aggregate Intrinsic Value
December 31, 2012		6,453,333		19,491,667	$	0.18		8.20		-
Options granted		-		-		-		-		-
Options exercised		-		-		-		-		-
Options forfeited		-		-		-		-		-
Additional options authorized		-		-		-		-		-
Outstanding at March 31, 2013		6,453,333		19,491,667	$	0.18		7.58		-
Exercisable at March 31, 2013		-		10,141,979	$	0.23		6.56		-

Schedule of Calculation of Numerator and Denominator in Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share and incorporates any additional income related to the change in fair value of derivative securities for the three-month period ending March 31, 2013:

	For the Three			For the Three
	Months Ended			Months Ended
	March 31,			March 31,
	2013			2012
Numerator:
Net (loss) for basic earning per share		(2,623,096	)		(3,152,001	)
Subtractions:
Change in fair value of derivative securities		-			-
Net (loss) for diluted earnings per share		(2,623,096	)		(3,152,001	)
Denominator:
Weighted average basic shares outstanding		155,871,102			108,041,084
Assumed conversion of dilutive securities
Warrants		-			-
Conversion feature - Convertible Debentures		-			-
Potentially dilutive common shares		-			-
Denominator for diluted earnings per share - Adjusted weighted average shares		155,871,102			108,041,084
(Loss) per share
Basic	$	(0.02	)	$	(0.03	)
Diluted	$	(0.02	)	$	(0.03	)

Inventory

Inventories consisted of the following at March 31, 2013 and December 31, 2012:

	March 31, 2013		December 31, 2012
Raw materials	$	158,420	$	155,022
Finished goods		47,055		47,055
Totals	$	205,475	$	202,077

XML

Subsequent Events

3 Months Ended

Mar. 31, 2013

Subsequent Events [Abstract]

Subsequent Events

7. Subsequent Events

Series C Convertible Preferred Stock

In April 2013, a shareholder converted 500,000 shares of Series C Convertible Preferred stock into 500,000 shares of restricted common stock.

Common Stock

In April 2013, holders of Convertible Debentures with a face value of $90,854 converted their Convertible Debentures into 1,585,581 shares of restricted common stock. In addition, associated with these Convertible Debentures, the Company paid $749 in accrued interest by issuing 13,064 shares of common stock.

XML

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2013

Accounting Policies [Abstract]

Revenue recognition

Revenue recognition

The Company recognizes revenues when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue from the sale of the Company’s products is generally recognized when title and risk of loss transfers to the customer, the terms of which are generally free on board shipping point. The Company uses customer purchase orders to determine the existence of an arrangement. The Company uses shipping documents and third-party proof of delivery to verify that title has transferred. The Company assesses whether the price is fixed or determinable based upon the terms of the agreement associated with the transaction. To determine whether collection is probable, the Company assesses a number of factors, including past transaction history with the customer and the creditworthiness of the customer.

Consolidation

Consolidation

The accompanying consolidated financial statements include the accounts of SpectraScience, Inc. and its wholly-owned subsidiaries LUMA, and International. All significant intercompany balances and transactions have been eliminated in consolidation.

Risks and Uncertainties

Risks and Uncertainties

The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. The Company's operations are subject to significant risk and uncertainties, including financial, operational, technological, regulatory and other risks associated with a short history of product sales, including the potential risk of business failure

Use of Estimates

Use of Estimates

The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Significant estimates made by management include, among others, realization of long-lived assets including intangible assets, assumptions used to value stock options, assumptions used to value the common stock issued and assumptions related to the determination of the fair value of the derivative components associated with the Company’s Convertible Debentures. Actual results could differ from those estimates.

Inventory Valuation

Inventory Valuation

The Company records its inventories at the lower of cost or market value, determined on a specific cost basis. The Company provides inventory allowances when conditions indicate that the selling price could be less than cost due to obsolescence and reductions in estimated future demand. The Company balances the need to maintain strategic inventory levels with the risk of obsolescence due to changing technology and customer demand levels. Unfavorable changes in market conditions may result in a need for additional inventory reserves that could adversely impact the Company’s gross margins. Conversely, favorable changes in demand could result in higher gross margins when the Company sells products.

Valuation of Long-lived Assets

Valuation of Long-lived Assets

The Company’s long-lived assets consist of fixed assets and intangible assets. Equipment is carried at cost and is depreciated over the estimated useful lives of the assets, which are generally two to three years, and leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the improvements. The straight-line method is used for depreciation and amortization. Intangible assets consist of patents, which are amortized using the straight-line method over the estimated useful lives of the patents. The Company does not capitalize external legal costs and filing fees associated with obtaining patents on its new discoveries. Acquired intellectual property is recorded at fair value and is amortized over its estimated useful life. The Company believes the useful lives assigned to these assets are reasonable. The Company assesses the recoverability of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. These computations utilize judgments and assumptions inherent in management’s estimate of future cash flows to determine recoverability of these assets. If management’s assumptions about these assets were to change as a result of events or circumstances, the Company may be required to record an impairment loss.

Convertible Debentures/Warrants

Convertible Debentures/Warrants

We account for our Convertible Debentures, associated warrants and related conversion features under the provisions of FASB Topic 470, Debt, or ASC 470, which requires the measurement and recognition of the fair values for all components related to the Convertible Debentures at the end of each reporting period. We estimate the fair value of the resulting Beneficial Conversion Feature ("BCF"), holders warrants and agent warrants at each measurement date using a combination of the Black-Scholes-Merton and modified Binomial Lattice option-pricing models. These standards require us to record the fair value of the Convertible Debentures, BCF and warrants at the time of issuance and to remeasure these values and record associated income statement expense or benefit at the end of each reporting period.

Stock-Based Compensation

Stock-Based Compensation

The Company accounts for stock-based compensation under the provisions of FASB ASC Topic 718, Compensation—Stock Compensation   (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company adopted ASC 718 on January 1, 2006. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes-Merton option-pricing model (the “Black-Scholes Model”). The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. The Company estimates forfeitures at the time of grant and revises its estimate in subsequent periods if actual forfeitures differ from those estimates.

The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC Topic 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.

All issuances of stock options or other equity instruments to employees and non-employees as the consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Any stock options issued to non-employees are recorded in expense and additional paid-in capital in shareholders’ equity over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options at the end of each reporting period.

As of March 31, 2013, the Company had one stock-based employee compensation plan under which it makes grants, the 2011 Equity Incentive Plan (the “EIP”). The EIP provides for the grant of incentive stock options (“ISOs”), nonqualified stock options (“NQSOs”) and restricted stock awards to full-time employees (who may also be directors) and NQSOs and restricted stock awards to non-employee directors, consultants, customers, vendors or providers of services. The exercise price of any ISO may not be less than the fair market value of the common stock on the date of grant and the term shall not exceed ten years. The amount reserved under the 2011 EIP is 15,000,000 shares of common stock.  At March 31, 2013, the Company had outstanding 19,491,667 options under the EIP and the Company’s prior Amended 2001 Stock Plan representing approximately 13% of the Company’s outstanding shares (10,141,979 of which were exercisable), with 6,453,333 available for future issuance under the 2011 EIP. Awards under the Company’s EIP generally vest over four years.

The fair value of options granted were estimated at the date of grant using a Black-Scholes Model which includes several variables including expected life, risk free interest rate, expected stock price volatility, stock option exercise patterns and expected dividend yield. The Company also must estimate forfeitures for employee stock options. These models and assumptions are complex and may change future expenses by increasing or decreasing stock-based compensation expense. There were no stock options granted during the three month period ended March 31, 2013. Management used the following weighted average assumptions to value stock options granted during the three months ended March 31, 2013 and 2012:

	2013		2012
Expected life	-		5 Years
Risk-free interest rate		-		.85	%
Expected volatility		-		113	%
Expected dividend yield		-		0	%

Management believes estimated forfeitures for employee stock options granted under the EIP would have a negligible effect on expenses because such forfeitures would be a very small percentage. Stock option grants have been to a group of individuals that have a high desire to see the Company succeed and have aligned themselves to that end.  

The expected lives used in the calculations were selected by management based on past experience, forward looking profit forecasts and estimates of what the trading price of the Company’s stock might be at different future dates.

The risk-free interest rates used in the calculations are the five-year U.S. Treasury rates as published on the date of the applicable stock option grant.

Volatility is a calculation based on fluctuations in the Company’s stock price over a historical time period consistent with the estimated life of the option.

Options outstanding that have vested and those that remain unvested as of March 31, 2013 are as follows:

			Weighted		Weighted Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual Term in		Intrinsic
	Shares		Price		Years		Value(1)
Vested		10,414,979	$	0.23		6.56	$	-
Unvested		9,349,688		0.13		8.69		-
Total		19,491,667	$	0.18		7.58	$	-

(1) These amounts represent the excess, if any, between the exercise price and $0.05, the closing market price of the Company’s common stock on March 31, 2013 as quoted on the Over-the-Counter Bulletin Board under the symbol “SCIE”.

Additional information with respect to stock option activity is as follows: 

			Outstanding Options
	Options Available For Grant		Plan Options Outstanding		Weighted Average Exercise Price Per Share		Weighted-Average Remaining Contractual  Term (years)		Aggregate Intrinsic Value
December 31, 2012		6,453,333		19,491,667	$	0.18		8.20		-
Options granted		-		-		-		-		-
Options exercised		-		-		-		-		-
Options forfeited		-		-		-		-		-
Additional options authorized		-		-		-		-		-
Outstanding at March 31, 2013		6,453,333		19,491,667	$	0.18		7.58		-
Exercisable at March 31, 2013		-		10,141,979	$	0.23		6.56		-

There were no options exercised during the three months ended March 31, 2013 and 2012. At March 31, 2013, total unrecognized estimated employee compensation cost related to non-vested stock options granted prior to that date is approximately $739,000, which is expected to be recognized over the next four years.

Earnings (Loss) Per Share

Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share is computed similarly to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and only if the additional common shares would be dilutive. Potentially dilutive shares of common stock that have been excluded from the calculation of the weighted average number of dilutive common shares for the three-months ended March 31, 2013 include common stock purchase warrants to acquire 70,210,121 shares of common stock, stock options to purchase 19,491,667 shares of common stock and preferred stock convertible into 3,585,000 shares of common stock.

The following table sets forth the computation of basic and diluted earnings per share and incorporates any additional income related to the change in fair value of derivative securities for the three-month period ending March 31, 2013:

	For the Three			For the Three
	Months Ended			Months Ended
	March 31,			March 31,
	2013			2012
Numerator:
Net (loss) for basic earning per share		(2,623,096	)		(3,152,001	)
Subtractions:
Change in fair value of derivative securities		-			-
Net (loss) for diluted earnings per share		(2,623,096	)		(3,152,001	)
Denominator:
Weighted average basic shares outstanding		155,871,102			108,041,084
Assumed conversion of dilutive securities
Warrants		-			-
Conversion feature - Convertible Debentures		-			-
Potentially dilutive common shares		-			-
Denominator for diluted earnings per share - Adjusted weighted average shares		155,871,102			108,041,084
(Loss) per share
Basic	$	(0.02	)	$	(0.03	)
Diluted	$	(0.02	)	$	(0.03	)

Inventories

Inventories

Inventories consisted of the following at March 31, 2013 and December 31, 2012:

	March 31, 2013		December 31, 2012
Raw materials	$	158,420	$	155,022
Finished goods		47,055		47,055
Totals	$	205,475	$	202,077

XML

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2013

Fair Value Measurements [Abstract]

Balances of Liabilities Measured at Fair Value on Recurring Basis

The following table presents the balances of liabilities measured at fair value on a recurring basis by level as of December 31, 2012 and March 31, 2013:

	Fair Value Measurements Using
	Quoted Prices in		Significant Other		Significant
	Active Markets for		Observable		Unobservable
	Identical Assets		Inputs		Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
As of December 31, 2012
Derivative liability	$	-	$	-	$	605,516	$	605,516
Warrant liability		-		-		1,730,044		1,730,044
Total	$	-	$	-	$	2,335,560	$	2,335,560

	Fair Value Measurements Using
	Quoted Prices in		Significant Other		Significant
	Active Markets for		Observable		Unobservable
	Identical Assets		Inputs		Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
As of March 31, 2013
Derivative liability	$	-	$	-	$	1,752,974	$	1,752,974
Warrant liability		-		-		2,635,856		2,635,856
Total	$	-	$	-	$	4,388,830	$	4,388,830

Changes in Liabilities with Significant Unobservable Inputs (Level 3)

The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the three months ended March 31, 2013:

	Warrant			Derivative			Total
	Liability			Liability			Liability
Balance, December 31, 2012	$	1,730,044		$	605,516		$	2,335,560
Issuance of convertible debt and warrants		762,111			929,156			1,691,267
Initial value of instruments in excess of face value of debt		(306,640	)		(447,376	)		(754,016	)
Change in estimated fair value		450,341			665,678			1,116,019
Balance, March 31, 2013	$	2,635,856		$	1,752,974		$	4,388,830

Derivative and Warrant Liabilities

Management used the following inputs to value the Derivative and Warrant Liabilities for the three-months ended March 31, 2013:

	Derivative Liability	Warrant Liability
Exercise Price	$0.0573 - $0.099	$0.075 - $0.1287
Risk Free rate	.11% - .14%	.77% - .88%
Expected Volatility	192.6% - 201.0%	173.1% - 177.6%
Expected Dividend Yield	-	-

XML

Additional Information with Respect to Stock Option Activity (Detail) (USD $)	3 Months Ended
	Mar. 31, 2013
Options Available For Grant	6,453,333
Options Available For Grant, Options granted	0
Options Available For Grant, Options exercised	0
Options Available For Grant, Options forfeited	0
Options Available For Grant, Additional options authorized	0
Outstanding Available For Grant	6,453,333
Options Available For Grant, Exercisable March 31, 2013	0
Plan Options Outstanding	19,491,667
Plan Options Outstanding, Options granted	0
Plan Options Outstanding, Options exercised	0
Plan Options Outstanding, Options forfeited	0
Plan Options Outstanding	19,491,667
Plan Options Outstanding, Exercisable March 31, 2013	10,141,979
Weighted Average ExercisePrice PerShare	$ 0.18
Weighted Average Exercise Price Per Share, Options granted	$ 0
Weighted Average Exercise Price Per Share, Options exercised	$ 0
Weighted Average Exercise Price Per Share, Options forfeited	$ 0
Outstanding, Weighted Average ExercisePrice PerShare	$ 0.18
Exercisable	$ 0.23
Weighted-Average Remaining ContractualTerm	7 years 6 months 29 days
Weighted-Average Remaining Contractual Term, Outstanding	7 years 6 months 29 days
Exercisable December 31, 2012, Weighted-Average Remaining Contractual Term	6 years 6 months 22 days
Aggregate Intrinsic Value	$ 0
Aggregate Intrinsic Value, Exercisable	0
Aggregate Intrinsic Value	$ 0	[1]

[1] These amounts represent the excess, if any, between the exercise price and $0.05, the closing market price of the Company's common stock on March 31, 2013 as quoted on the Over-the-Counter Bulletin Board under the symbol "SCIE".

XML

Fair Value Measurements - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in probability of down round financing	10.00%
Percentage change in derivative liability down round financing	7.00%
Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in stock price	0.030
Assumed stock prices	80.00%
Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in stock price	0.039
Assumed stock prices	95.00%

XML

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (DEFICIT) (USD $)	Total	Consultants	Employees	Preferred Stock	Common Stock	Additional Paid-In Capital	Additional Paid-In Capital Consultants	Additional Paid-In Capital Employees	Accumulated Deficit
Beginning Balance at Dec. 31, 2012	$ (1,576,408)			$ 35,850	$ 1,522,297	$ 35,491,603			$ (38,626,158)
Beginning Balance (in shares) at Dec. 31, 2012				3,585,000	152,229,665
Stock based compensation		2,106	99,642				2,106	99,642
Common Stock issued for services	55,149				30,000	25,149
Common Stock issued for services (in shares)					3,000,000
Conversion of convertible debt	176,643				24,249	152,394
Conversion of convertible debt (In shares)					2,424,900
Net loss	(2,623,096)								(2,623,096)
Ending Balance at Mar. 31, 2013	$ (3,865,964)			$ 35,850	$ 1,576,546	$ 35,770,894			$ (41,249,254)
Ending Balance (in shares) at Mar. 31, 2013				3,585,000	157,654,565

XML

Shareholders' Equity

3 Months Ended

Mar. 31, 2013

Equity [Abstract]

Shareholders' Equity

4. Shareholders’ Equity

Common Stock

In January 2013, the Company issued 3,000,000 shares of restricted common stock to two vendors for services. The fair value of the vested portion of these shares was determined to be $55,149.

In February of 2013, holders of Convertible Debentures with a face value of $126,316 converted their debentures into 2,204,453 shares of restricted common stock. In addition, associated with these debentures, the Company paid $12,632 in accrued interest by issuing 220,447 shares of restricted common stock.

Warrants

During the three-months ended March 31, 2013, in conjunction with the sale of Convertible Debentures, the Company issued five-year common stock purchase warrants to acquire 7,458,437 shares to holders of the Debentures and 2,237,531 similar warrants as compensation to Agents. These warrants have an exercise price of $0.0745 per share.

Convertible Debentures

During the three-months ended March 31, 2013, the Company entered into subscription agreements with accredited investors to purchase an aggregate principal amount of $854,737 of Convertible Debentures initially convertible into shares of restricted common stock at a conversion price of $0.0573.

XML

Balances of Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Mar. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 1,752,974	$ 605,516
Warrant liability	2,635,856	1,730,044
Total	4,388,830	2,335,560
Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	1,752,974	605,516
Warrant liability	2,635,856	1,730,044
Total	$ 4,388,830	$ 2,335,560

XML

Options Outstanding Vested and Remain Unvested (Detail) (USD $)	3 Months Ended
	Mar. 31, 2013		Dec. 31, 2012
Summary Of Options Outstanding Vested and Remain Unvested [Line Items]
Number of Shares	19,491,667		19,491,667
Weighted Average Exercise Price	$ 0.18		$ 0.18
Weighted Average Remaining Contractual Term in Years	7 years 6 months 29 days
Aggregate Intrinsic Value	$ 0	[1]	$ 0
Stock Options Vested
Summary Of Options Outstanding Vested and Remain Unvested [Line Items]
Number of Shares	10,414,979
Weighted Average Exercise Price	$ 0.23
Weighted Average Remaining Contractual Term in Years	6 years 6 months 22 days
Aggregate Intrinsic Value	0	[1]
Stock Options Unvested
Summary Of Options Outstanding Vested and Remain Unvested [Line Items]
Number of Shares	9,349,688
Weighted Average Exercise Price	$ 0.13
Weighted Average Remaining Contractual Term in Years	8 years 8 months 9 days
Aggregate Intrinsic Value	$ 0	[1]

[1] These amounts represent the excess, if any, between the exercise price and $0.05, the closing market price of the Company's common stock on March 31, 2013 as quoted on the Over-the-Counter Bulletin Board under the symbol "SCIE".